BLRD Research Career Scientist Award Application

BLRD 研究职业科学家奖申请

• 批准号: 10594005
• 负责人: PRAN K DATTA
• 金额: --
• 依托单位: BIRMINGHAM VA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-04-01 至 2027-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10594005
• 关键词: Academia; Afghanistan; Age Years; Alabama; American; Award; Basic Cancer Research; Binding Proteins; Biological Markers; Brain; Cancer Etiology; Cancer Patient; Cessation of life; Chemoresistance; Clinical; Cloning; Collaborations; Colorectal; Colorectal Cancer; Combined Modality Therapy; Communication; Death Records; Development; Diagnosis; Diagnostic; Discipline; Disseminated Malignant Neoplasm; Distant Metastasis; Drug resistance; Epithelium; Faculty; Family member; Fluorouracil; Funding; Gastroenterology; Grant; Health; Healthcare; Hematology; Hepatology; Human; Institution; International; Iraq; Journals; Knock-in Mouse; Knockout Mice; Korean War; Laboratories; Letters; Lung Neoplasms; Malignant Neoplasms; Malignant neoplasm of lung; Medical center; Mentors; Metastatic malignant neoplasm to brain; MicroRNAs; Military Personnel; Molecular; Mus; Nature; Neoplasm Metastasis; Non-Small-Cell Lung Carcinoma; Nucleic Acids; Oncogenes; Oncogenic; Oncology; Oncoproteins; Organoids; Paper; Pathogenesis; Patients; Pharmacologic Substance; Phase; Play; Population; Positioning Attribute; Postdoctoral Fellow; Protein Array; Proteins; Publications; Regulation; Research; Research Personnel; Risk; Role; Scientist; Seminal; Serum; Services; Signal Transduction; Small Interfering RNA; Smoke; Smoking; Therapeutic; Tobacco use; Training; Transforming Growth Factor beta; Transforming Growth Factor beta Receptors; Translational Research; Tumor Suppressor Genes; Tumorigenicity; Universities; Veterans; Vietnam; War; Woman; Work; active duty; anticancer research; beta catenin; career; chemotherapy; cigarette smoking; circulating microRNA; clinical predictors; combat; embryonic stem cell; high risk; in vivo Model; innovation; intestinal epithelium; military veteran; mortality; nanocarrier; nanoformulation; nanoparticle; nanotherapy; notch protein; novel; novel strategies; oxaliplatin; predictive marker; professor; programs; research and development; response; screening; serine-threonine kinase receptor-associated protein; stem-like cell; stemness; therapeutic target; translational cancer research; tumor; tumor progression

Dr. Pran K. Datta is currently a Research Microbiologist at the Birmingham VA Medical Center (BVAMC), AL, and a Professor at the VA-affiliated University of Alabama at Birmingham (UAB). He has a long-standing track record in the mechanistic studies of colorectal (CRC) and lung cancer. Since 2010, he has been contributing significantly to VA research and services through training, mentoring, and collaboration with VA investigators. His established expertise in basic and translational cancer research has also attracted investigators from diverse disciplines at the VA Medical Centers in the US, Vanderbilt University, and UAB, which has led to collaborative grants and high-impact publications. A seminal discovery from Dr. Datta's lab is the identification and cloning of a TGF-ß-receptor binding protein STRAP (Serine Threonine Kinase Receptor Associated Protein) that inhibits TGF-ß signaling and activates Wnt/ß-catenin and Notch signaling. The second seminal contribution of his study is to establish the role of STRAP in activating the stemness of cancer stem-like cells. His third seminal contribution is to identify a smoking-regulated miRNA signature that promotes NSCLC progression and chemoresistance. His high impact research resulted in more than 70 papers and reviews in reputable top-tier scientific journals (some of them with impact factor range 8.7-22.7). The fundamentals of the following projects are based on these high impact and highly cited papers. Around 20 of his papers are cited more than 100 times each. Project I: Translational research on colorectal cancer (CRC) pathogenesis and targeting by nanotherapy. During the last 40 years, the proportion of CRC has increased by about 15% in the veteran population and thus constitutes a significant risk for all veterans and their family members, including women, especially over 50 years of age. Consistent with this, there were more than 52,000 new cases of colorectal cancer cases in VA during the last 5 years. To combat this problem, the PI's lab will therapeutically target the pro-oncogenic functions of STRAP by siRNA-based nanoformulation in potential treatment of CRC patients as well as by sensitizing 5-FU and/or Oxaliplatin based chemotherapy. Project II: Circulating microRNAs as predictive biomarkers for brain metastasis in non-small cell lung cancer (NSCLC). Consistent with the fact that lung cancer remains the leading cause of cancer death in the US veteran population, there were 41,780 new lung cancer cases and 19,543 lung cancer deaths among the VA population during the last 5 years. The percentage of active-duty military personnel who smoked was highest during the Vietnam and Korean Wars (75%). Similarly, 60% of Afghanistan and Iraq War veterans used tobacco. The death records of 52,000 veterans of Vietnam War showed that these veterans died of lung cancer at a 58% higher rate than veterans who did not serve there. To this end, Dr. Datta's lab is trying to identify a miRNA signature in primary lung tumors that predicts NSCLC metastasis to the brain. Then this miRNA signature will be validated using serum to stratify NSCLC patients at high risk for developing brain metastasis and investigate their function in NSCLC progression and metastasis. In addition to conducting these highly innovative and high impact research programs, Dr. Datta has been recognized for his exceptional contributions to training, mentoring, and services at the local and national VA. As the Director of Research in the Hematology and Oncology Division and of the T32 Training Grant, Dr. Datta oversaw the research development and mentored junior faculty and clinical and postdoctoral fellows; a number of those are in academia with high positions. Taken together, the RCS Award is expected to assist him develop high-impact diagnostics and therapies for veterans and other Americans in need.

Pran K.Datta博士目前是伯明翰退伍军人医学中心的研究微生物学家 (BVAMC)，AL，退伍军人事务部附属阿拉巴马大学伯明翰分校(UAB)教授。他有一个 在结直肠癌(CRC)和肺癌的机制研究方面有着长期的跟踪记录。自2010年以来，他一直 通过培训、指导和合作，为退伍军人管理局的研究和服务做出重大贡献 退伍军人事务部调查人员。他在基础和转化性癌症研究方面的成熟专业知识也吸引了 来自美国退伍军人医学中心、范德比尔特大学和UAB的不同学科的研究人员， 这导致了合作赠款和高影响力的出版物。 达塔博士实验室的一项开创性发现是鉴定和克隆了一种转化生长因子受体结合 蛋白条带(Serine Threonine Kinase Receptor Related Protein)抑制转化生长因子-β信号转导和 激活Wnt/？-catenin和Notch信号。他的研究的第二个开创性贡献是建立了 条带在激活肿瘤干细胞样细胞干性中的作用。他的第三个开创性贡献是识别 吸烟调节的miRNA信号促进非小细胞肺癌进展和化疗耐药。他的高潮 影响研究在著名的顶级科学期刊上发表了70多篇论文和评论(其中一些 影响因子在8.7~22.7之间)。以下项目的基本面是基于这些高 影响和高被引用的论文。他的大约20篇论文每篇被引用超过100次。 项目I：结直肠癌(CRC)发病机制和靶向的翻译研究 纳米疗法。在过去的40年里，退伍军人中结直肠癌的比例增加了约15% 这对所有退伍军人及其家庭成员，包括妇女，构成重大风险， 尤其是50岁以上的人。与此相一致的是，有超过52,000例新的结直肠癌病例 退伍军人事务部最近5年的癌症病例。为了解决这个问题，PI的实验室将从治疗上瞄准 SiRNA纳米制剂在结直肠癌治疗AS中的促癌作用 以及通过敏化基于5-FU和/或奥沙利铂的化疗。 项目II：循环中的microRNA作为非小细胞脑转移的预测生物标记物 肺癌(NSCLC)。与肺癌仍然是#年癌症死亡的主要原因这一事实相一致 在美国退伍军人中，有41,780例新的肺癌病例和19,543例肺癌死亡 过去5年的退伍军人人数。现役军人吸烟的百分比为 越南战争和朝鲜战争期间最高(75%)。同样，60%的阿富汗和伊拉克战争退伍军人 用过的烟草。5.2万名越战老兵的死亡记录显示，这些老兵死于肺病 癌症的发病率比没有在那里服役的退伍军人高58%。为此，达塔博士的实验室正试图 在原发肺肿瘤中确定一个miRNA信号，以预测NSCLC脑转移。然后就是这个 将使用血清验证miRNA签名，以对脑发育高危的非小细胞肺癌患者进行分层 并探讨其在非小细胞肺癌进展和转移中的作用。 除了开展这些极具创新性和影响力的研究项目外，达塔博士还 他在地方和国家的培训、指导和服务方面的杰出贡献得到了表彰 弗吉尼亚州作为血液和肿瘤科和T32培训基金的研究主管，Dr。 达塔负责监督研究进展，并指导初级教员以及临床和博士后研究员；a 其中许多人在学术界担任高级职位。总而言之，RCS奖预计将有助于 他为退伍军人和其他有需要的美国人开发高影响力的诊断和治疗方法。